AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs

SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression, the AHA says.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news